32 results on '"Liu, Chengfei"'
Search Results
2. MP20-11 ENZALUTAMIDE RESISTANCE RESULTS IN IMMUNOSUPPRESSIVE ALTERATIONS IN PROSTATE TUMOR IMMUNE MICROENVIRONMENT
3. MP20-16 NOVEL FUNCTION OF PTUPB IN AKR1C3/AR/AR-V7 AXIS INHIBITION AND ENZALUTAMIDE SENSITIZATION IN ADVANCED PROSTATE CANCER
4. PD04-09 COMBINATION TREATMENT WITH HSP70/STUB1 MODULATOR AND ENZALUTAMIDE YIELDS SYNERGISTIC ACTIVITY IN ADVANCED PROSTATE CANCER
5. MP27-08 EVALUATING THE EFFICACY OF A NOVEL AKR1C3 INHIBITOR IN PATIENT-DERIVED PROSTATE CANCER CELL LINE AND XENOGRAFT MODELS
6. PD07-02 TARGETING WNT5A/FZD2 SIGNALING OVERCOMES RESISTANCE TO ENZALUTAMIDE IN ADVANCED PROSTATE CANCER
7. MP37-03 MODULATING HSP70/STUB1 MACHINERY BY NOVEL SMALL MOLECULES OVERCOMES ENZALUTAMIDE RESISTANCE IN LETHAL PROSTATE CANCER
8. PD59-09 TARGETING STEROID SULFATASE WITH NOVEL INHIBITORS SUPPRESSES CRPC TUMOR GROWTH AND IMPROVES RESPONSE TO ENZALUTAMIDE
9. MP22-05 AKR1C3 PROMOTES AR-V7 PROTEIN STABILIZATION AND CONFERS ANTI-ANDROGEN RESISTANCE IN ADVANCED PROSTATE CANCER
10. MP22-08 PROTEOSTASIS BY HSP70/STUB1 COMPLEX REGULATES ANDROGEN RECEPTOR VARIANTS EXPRESSION AND CONFERS RESISTANCE TO ENZALUTAMIDE AND ABIRATERONE
11. MP22-02 GNRH ANTAGONISTS HAVE DIRECT INHIBITORY EFFECTS ON CASTRATION-RESISTANT PROSTATE CANCER VIA INTRACRINE ANDROGEN AND AR-V7 EXPRESSION
12. MP68-15 TARGETING STEROID SULFATASE SUPPRESSES ANDROGEN RECEPTOR SIGNALING AND TUMOR GROWTH IN CRPC
13. MP68-09 OVERCOMING PROSTATE CANCER THERAPEUTIC RESISTANCE BY MODULATING MITOCHONDRIA-MEDIATED CELL METABOLISM AND DEATH SIGNALING
14. MP52-01 COMBINATION OF INDOMETHACIN AND ENZALUTAMIDE TO TREAT CASTRATION-RESISTANT PROSTATE CANCER
15. MP29-08 HSD3B1 PREFERENTIALLY UTILIZES PREGNENOLONE TO PROMOTE RESISTANCE TO ANTI-ANDROGENS IN PROSTATE CANCER
16. MP29-02 ELUCIDATING CROSS-RESISTANCE BETWEEN TAXANES AND NEXT-GENERATION ANTI-ANDROGENS IN CASTRATION RESISTANT PROSTATE CANCER
17. PD37-12 EVALUATION OF NICLOSAMIDE AS A POTENT INHIBITOR OF ANDROGEN RECEPTOR VARIANTS TO OVERCOME RESISTANCE TO ABIRATERONE AND ENZALUTAMIDE IN ADVANCED PROSTATE CANCER
18. MP57-19 TARGETING AKR1C3 ACTIVATION BY INDOMETHACIN OVERCOMES RESISTANCE TO ENZALUTAMIDE AND ABIRATERONE
19. MP99-15 TAXANE RESISTANCE IN PROSTATE CANCER: A ROLE FOR MIRNA 181A
20. MP99-02 OVEREXPRESSION OF HSD3B1 CONFERS RESISTANCE TO ENZALUTAMIDE IN PROSTATE CANCER
21. MP83-09 ELUCIDATING CROSS-RESISTANCE BETWEEN DOCETAXEL AND CABAZITAXEL IN CASTRATION RESISTANT PROSTATE CANCER
22. MP46-05 INHIBITION OF CONSTITUTIVELY ACTIVE STAT3 AND AR VARIANTS REVERSES ENZALUTAMIDE RESISTANCE IN ADVANCED PROSTATE CANCER CELLS
23. MP46-02 UP-REGULATION OF GLUCOSE METABOLISM BY NF-κB2/P52 MEDIATES ENZALUTAMIDE RESISTANCE IN PROSTATE CANCER CELLS
24. MP46-01 AKR1C3 ACTIVATION AND INTRACRINE ANDROGENS CONFER RESISTANCE TO ENZALUTAMIDE
25. MP46-03 NF-KAPPAB2/P52:C-MYC:HNRNPA1 REGULATORY PATHWAY CONTROLS EXPRESSION OF ANDROGEN RECEPTOR SPLICE VARIANTS AND ENZALUTAMIDE SENSITIVITY IN PROSTATE CANCER
26. MP24-08 INHIBITION OF CONSTITUTIVELY ACTIVE STAT3 REVERSES ENZALUTAMIDE RESISTANCE IN LNCAP DERIVATIVE PROSTATE CANCER CELLS
27. MP24-07 NF-KAPPAB2/P52 INDUCES RESISTANCE TO ENZALUTAMIDE IN PROSTATE CANCER: ROLE OF ANDROGEN RECEPTOR AND ITS VARIANTS
28. 974 FUNCTIONAL P53 DETERMINES DOCETAXEL SENSITIVITY IN PROSTATE CANCER CELLS
29. 483 RHOGDIÁ SUPPRESSES GROWTH AND SURVIVAL OF PROSTATE CANCER CELLS BY REGULATING ANDROGEN RECEPTOR (AR) SIGNALING PATHWAY
30. 782 SANGUINARINE INHIBITS STAT3 ACTIVATION AND TUMOR GROWTH IN PROSTATE CANCER CELLS
31. 1619 ANDROGRAPHOLIDE IS A NOVEL INHIBITOR OF INTERLEUKIN-6 AND SUPPRESSES PROSTATE TUMOR GROWTH
32. 415 ANDROGRAPHOLIDE TARGETS AR PATHWAY IN CASTRATION-RESISTANT PROSTATE CANCER
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.